Analyst Price Targets — SNSE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 28, 2026 11:06 am | Christopher Liu | Loop Capital Markets | $50.00 | $16.65 | StreetInsider | Lucid Capital Markets Starts Sensei Biotherapeutics (SNSE) at Buy |
| May 13, 2024 4:20 pm | Sudan Loganathan | Stephens | $5.00 | $1.57 | TheFly | Sensei Biotherapeutics initiated with an Overweight at Stephens |
| December 13, 2022 1:13 pm | — | Citigroup | $6.00 | $1.74 | Benzinga | Citigroup Initiates Coverage On Sensei Biotherapeutics with Buy Rating, Announces Price Target of $6 |
Latest News for SNSE
AUSTIN, Texas--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has changed its corporate name to Faeth Therapeutics, Inc. (the “Company”). The Company's common stock is expected to begin trading on the Nasdaq Capital Market under the new ticker symbol “FTH” on June 16, 2026, and the Company has launched a new corporate website at www.faeththerapeutics.com. On June 10, 2026,…
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on June 1, 2026, the Compensation Committee of Sensei's Board of Directors granted
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on June 1, 2026, the Compensation Committee of Sensei's Board of Directors granted three new employees options to purchase an aggregate of 19,300 shares of the Company's common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted pursuant to the Company's 2026…
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. â
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. “The first quarter of 2026 was transformational for the Company, with the acquisition of Faeth Therapeutics and the concurrent $200 million private placement in February, supported by a group of leading life sciences investors,” said…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for SNSE.
Senate Trading
No Senate trades found for SNSE.
U.S. House Trading
No House trades found for SNSE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.